What is the liver function test (LFT) derangement pattern in hepatic inflammation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hepatic inflammation typically presents with a pattern of elevated liver function tests (LFTs) characterized by predominant increases in aminotransferases (ALT and AST), as seen in hepatocellular injury, which is the most common cause of abnormal LFTs 1. The pattern of LFT derangement is crucial in distinguishing hepatocellular injury from cholestatic or mixed patterns, guiding diagnostic workup and treatment approaches.

  • In acute inflammation, ALT is often higher than AST, while chronic inflammation may show an AST:ALT ratio greater than 1.
  • Alkaline phosphatase and gamma-glutamyl transferase may be mildly elevated, but less prominently than aminotransferases. Initial management includes identifying and removing the underlying cause, whether it's viral hepatitis, alcohol, medications, or autoimmune conditions.
  • For medication-induced inflammation, discontinue the offending drug, as recommended in the evaluation of patients with treatment-emergent ALT elevation during clinical trials with anti-cancer drugs 1.
  • For alcoholic hepatitis, complete alcohol cessation is essential.
  • For viral hepatitis, specific antivirals may be indicated depending on the virus type.
  • For autoimmune hepatitis, prednisone starting at 40-60mg daily with gradual taper and addition of azathioprine 50-150mg daily as a steroid-sparing agent is typically recommended. Supportive care includes adequate hydration, nutritional support, and monitoring for complications like coagulopathy or encephalopathy.
  • Serial LFT monitoring every 1-2 weeks initially is important to assess response to treatment, and to evaluate for treatment-related GI and hepatic adverse effects in patients undergoing drug treatment for COVID-19 1. The R value, calculated as (ALT/ALT ULN)/(ALP/ALP ULN), can help characterize the phenotype of injury observed with a particular drug, with an R value ≥5 defining hepatocellular injury, whereas R ≤ 2 indicates cholestatic injury, and R > 2 < 5 is consistent with a mixed injury pattern 1.

From the Research

Hepatic Inflammation and LFT Derangement Pattern

Hepatic inflammation is a complex process that involves the activation of various immune cells and the release of pro-inflammatory cytokines, which can lead to liver damage and derangement of liver function tests (LFTs) 2, 3. The pattern of LFT derangement can vary depending on the underlying cause of hepatic inflammation.

Causes of Hepatic Inflammation

Some common causes of hepatic inflammation include:

  • Viral hepatitis, such as hepatitis B and C 4
  • Alcohol-induced liver disease 3
  • Non-alcoholic steatohepatitis (NASH) 3
  • Autoimmune hepatitis 3

LFT Derangement Pattern

The LFT derangement pattern in hepatic inflammation can include:

  • Elevated liver enzymes, such as alanine transaminase (ALT) and aspartate transaminase (AST) 2
  • Elevated bilirubin levels 3
  • Decreased albumin levels 3
  • Prolonged prothrombin time (PT) and international normalized ratio (INR) 5, 6

Treatment and Management

Treatment and management of hepatic inflammation depend on the underlying cause and can include:

  • Antiviral medications, such as tenofovir and entecavir, for viral hepatitis 5, 6
  • Corticosteroids and immunosuppressants for autoimmune hepatitis 3
  • Lifestyle modifications, such as weight loss and alcohol cessation, for NASH and alcohol-induced liver disease 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.